Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedGenesis has entered into an agreement with Amgen, which grants MedGenesis worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries. As part of the license agreement, Amgen now holds a small equity stake in MedGenesis.
Subscribe to our email newsletter
In parallel, Biovail Laboratories International, a subsidiary of Biovail, and MedGenesis have concluded an agreement to collaborate on the development of GDNF in parkinson’s disease and potentially other CNS indications. Biovail, which is also a party to the Amgen license for CNS indications, has a co-exclusive license to exploit GDNF in certain countries (including the US, Canada, Japan and European countries).
MedGenesis has also granted Biovail a license to its convection enhanced delivery (CED) platform for use with GDNF in CNS indications. MedGenesis and Biovail will initially focus on the development of GDNF for parkinson’s disease. GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells.
Erich Mohr, chairman and CEO of MedGenesis, said: “This license of GDNF from Amgen presents MedGenesis and Biovail with an exciting opportunity to develop a potential breakthrough therapy for the treatment of patients with parkinson’s disease. We believe that our convection enhanced delivery approach will result in accurate, targeted delivery of GDNF to the regions of the brain affected by this severely debilitating disease and holds the promise of providing patients for the first time with a treatment which could potentially modify the disease, rather than just treat the symptoms.
“We are also excited to have licensed the GDNF protein exclusively from Amgen in non-CNS indications and to have the opportunity to investigate additional applications of the molecule through similar collaborations with other potential partners.”